Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. The second highest contributing market is APAC, generating 33.2%

52

52

pharmaphorum

DECEMBER 12, 2022

Updated results from the ADVANCE IV study of Vyvgart (efgartigimod alfa) showed that more than half of patients with ITP treated with Argenx’ drug showed an improvement in platelet counts, which are dramatically reduced in the disorder. After 24 weeks, 21.8%

Immunization 52

Immunization Labelling FDA 52

pharmaphorum

APRIL 5, 2022

It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes. ” Image by Pexels from Pixabay .

Labelling 52

Labelling Chemotherapy Immunization 52

pharmaphorum

NOVEMBER 24, 2022

Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments. One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

Labelling 52

Labelling Hospitals 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Results suggest durable epigenetic re-wiring and provide rationale for intermittent clinical dosing.

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

JANUARY 21, 2022

It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance.

Insurance 52

Insurance Vaccines 52

pharmaphorum

DECEMBER 17, 2021

Biogen and partner Eisai have said they will provide details next March for the confirmatory trial that will be needed to upgrade the drug’s accelerated approval for controversial Alzheimer’s drug Aduhelm to a full one.

FDA 52

FDA 52

pharmaphorum

MAY 17, 2021

Empaveli’s label covers treatment-naïve PNH patients as well as those who want to switch from Soliris or Ultomiris, and is based on the phase 3 PEGASUS trial in 80 patients which compared the drug to Soliris over a 16-week period. The post Apellis set to take on Alexion as FDA clears PNH drug Empaveli appeared first on.

FDA 52

FDA Labelling Vaccines 52

pharmaphorum

APRIL 14, 2022

million price tag. The gene therapy has already been approved for marketing in the EU and UK, where it was launched at a cost of around $1.7 The FDA is currently reviewing beti-cel – also known as Zynteglo (betibeglogene autotemcel) – as a treatment for patients with beta thalassaemia who require regular blood transfusions.

FDA 64

FDA 64

pharmaphorum

JUNE 2, 2022

R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ It is estimated that between 3.5

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Viseven

NOVEMBER 30, 2022

From AI-based drug discovery to running virtual cohorts for clinical trials or doing continuous manufacturing instead of batch manufacturing, from launching a project effectively to doing real-world tickets, there is technology penetration all along the value chain. And then all the technology will be applied to it.

52

52

pharmaphorum

AUGUST 26, 2022

million for the one-shot therapy – in other words, after any discounts that it may offer or outcomes-based agreements – aiming to launch first in Germany followed by France. BioMarin has said Roctavian will be available at a ‘net’ price of around €1.5 million spread over five years. million spread over five years.

FDA 111

FDA 111

Pharmaceutical Technology

JANUARY 27, 2023

On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. Cablivi stops platelets from clumping together, which prevents small clots, and can be used along with other drugs that suppress the immune system.

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

FEBRUARY 26, 2021

In 1894, J&J’s heritage baby business began, by the launch of maternity kits. Some of the most well-known Janssen products include diarrhoea treatment, Immodium (loperamide), antipsychotic Risperdal (risperidone) and Alzheimer’s disease drug, Reminyl (galantamine). billion) hit the company in 2019.

Vaccines 124

Vaccines Labelling Communication 124

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research.

Vaccines 90

Vaccines 90

Pharmaceutical Technology

MARCH 17, 2023

These agreements have been particularly propelled by the recent rise in inflationary pressures and pharmaceutical market instability, pushing healthcare systems to find new ways to reduce risks associated with new drugs. Thus, a higher risk score reflects a more hostile market access environment and drug launch in a geographical area.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. The drug was approved to treat type 2 diabetes mellitus in May. million in Q3.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. The drug was approved to treat type 2 diabetes mellitus in May. The drug was approved to treat type 2 diabetes mellitus in May. million in Q3.

Insurance 98

Insurance Labelling Communication FDA 98